Xbrane Biopharma AB (publ)

Total Valuation

Xbrane Biopharma AB (publ) carries a market capitalization of 130.27M, placing it among publicly traded companies globally. Its enterprise value stands at 38.29B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Share Statistics

Xbrane Biopharma AB (publ) currently has 1.53B shares outstanding.

Valuation Ratios

Xbrane Biopharma AB (publ) trades at a trailing price-to-earnings ratio of 481.88. The price-to-sales ratio is 177.93, and the price-to-book ratio stands at -37.57.

Enterprise Valuation

On an enterprise value basis, Xbrane Biopharma AB (publ) trades at an EV/EBITDA multiple of 10,925.69 and an EV/FCF ratio of 297.80. The EV/Sales ratio of 178.00 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 10,925.69 provides insight into valuation relative to core operating earnings.

Financial Position

Xbrane Biopharma AB (publ) maintains a current ratio of 1.69, meaning it holds 1.7x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 5.20, indicating elevated leverage, while an interest coverage ratio of 0.12 demonstrates limited ability to service its debt obligations.

Financial Efficiency

Taxes

Stock Price Statistics

Xbrane Biopharma AB (publ)'s stock has declined approximately -64.91803% over the past 52 weeks. The 50-day moving average sits at 10.51, while the 200-day moving average is 11.46.

Income Statement

Over the trailing twelve months, Xbrane Biopharma AB (publ) generated 215.14M in revenue and converted that into 79.44M in net income, yielding earnings per share of -0.03. EBITDA reached 3.51M, while operating income came in at 3.51M.

Balance Sheet

Xbrane Biopharma AB (publ) holds 5.86M in cash and equivalents against 20.00M in total debt, resulting in a net debt position of 14.14M. Total book value stands at -1.02B, with working capital of 149.53M providing operational flexibility.

Cash Flow

Xbrane Biopharma AB (publ) produced -54.69M in operating cash flow over the past twelve months. After subtracting -138.05M in capital expenditures, free cash flow totaled -192.73M - equivalent to -0.16 per share.

Margins

Xbrane Biopharma AB (publ) operates with a gross margin of 68.78, reflecting its pricing power and cost economics. The operating margin of 1.63 and net profit margin of 36.93 provide insight into operational efficiency.

Dividends & Yields

Stock Splits

Xbrane Biopharma AB (publ)'s most recent stock split took place on October 17, 2025 with a 125:1 split ratio.

Scores

Xbrane Biopharma AB (publ) posts an Altman Z-Score of 101.80, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.